key: cord-0786818-zpgvh8ta authors: Lai, Quirino; Spoletini, Gabriele; Bianco, Giuseppe; Graceffa, Dario; Agnes, Salvatore; Rossi, Massimo; Lerut, Jan title: SARS‐CoV2 and immunosuppression: a double‐edged sword date: 2020-07-08 journal: Transpl Infect Dis DOI: 10.1111/tid.13404 sha: 4964c466c53df8c8a9b0cf4d5684a45e3f796229 doc_id: 786818 cord_uid: zpgvh8ta Severe acute respiratory syndrome Coronavirus 2 (SARS‐Cov2) outbreak has caused a pandemic rapidly impacting on the way of life of the entire world. This impact in the specific setting of transplantation and immunosuppression has been poorly explored to date. Discordant data exist on the impact of previous coronavirus outbreaks on immunosuppressed patients. Overall, only a very limited number of cases have been reported in literature, suggesting that transplanted patients not necessarily present an increased risk of severe SARS‐Cov2‐related disease compared to the general population. We conducted a literature review related to the impact of immunosuppression on coronavirus infections including case reports and series describing immunosuppression management in transplant recipients. The role of steroids, calcineurin inhibitors and mycophenolic acid has been explored more in detail. A point‐in‐time snapshot of the yet released literature and some considerations in relation to the use of immunosuppression in SARS‐Cov2 infected transplant recipients are provided here for the physicians dealing with immunocompromised patients. Severe acute respiratory syndrome Coronavirus 2 (SARS-CoV2) is a new virus causing a zoonosis originating from bats (COronaVIrus , as recently reported in the literature. Following its outbreak in China, SARS-CoV2 has led to a worldwide spread, being declared by This article is protected by copyright. All The leading cause of mortality is the acute respiratory distress syndrome (ARDS) following viral pneumonia. ARDS can translate into a devastating end-stage lung disease for which treatment options are limited. Furthermore, many ARDS cases may progress to pulmonary fibrosis, another clinically devastating lung disease for which also limited curative strategies are available. Therefore, understanding the immunological mechanisms of virus-related ARDS represents a high-priority research topic. When epidemics occur, transplant patients raise concern due to their vulnerability to infections. Whether immunosuppressants modify the transition from SARS-CoV2 contagion to pneumonia and, ultimately, ARDS is not known yet. The role of the immunological mechanisms causing coronavirus (CoV)-related ARDS in the context of transplantation can be seen as a "bench-to-bedside" type experiment on the impact of immunosuppressive drugs in the course of the respiratory disease. The pathogenesis of CoV-related ARDS includes complement and coagulation cascade activation, and proinflammatory and profibrotic cytokine responses. After infecting the pneumocytes, CoV induces a massive signaling response in infected lungs, favoring thereby the release of several proinflammatory cytokines and chemokines, including IL-6, TNFα, IL-1β, and CCL2. These molecules recruit inflammatory cells to the site of infection, such as neutrophils and cytotoxic T cells. These cells may damage tissues leading to vascular leakage and fibrosis formation. 1 In some cases, the inflammatory status can become systemic, leading to a cytokine storm syndrome with the characteristics of a secondary hemophagocytic lymphohistiocytosis. Therefore, the use of immunosuppressants such as corticosteroids or anti-cytokine drugs like IL-1 blockade (anakinra) and IL-6 receptor blockade (tocilizumab) has been proposed. 2 With the present work, we aimed to review the existing literature on the impact of immunosuppression on coronaviruses infections and the development of severe lower respiratory tract disease. Secondly, we retrieved and summarized the recently published literature describing the course of CoV infections in transplant recipients. This article is protected by copyright. All rights reserved strategy was "SARS-CoV2" OR " COVID-19" AND "transplantation". We included all the studies describing the management of immunosuppression in transplant recipients. Potential case duplicates were ruled out by analysis of demographic characteristics of the included patients and country and institution of origin of the reports. Several studies reported the specific role of an immunocompromised status as a possible risk factor for CoV-related pneumonia. A study based on 85 immunocompromised vs. 1,152 nonimmunocompromised children did not show a different prevalence of CoV-related pneumonia and severe pneumonia (22% vs. 26% and 15% vs. 11%, respectively). However, the immunocompromised status was a risk factor for severe respiratory disease. 3 Another study on five Rhesus macaques showed that immunosuppression with cyclophosphamide and dexamethasone leads to a significantly higher level of the Middle East respiratory syndrome (MERS)-CoV replication in the respiratory tissues. Despite this increased viral replication, pathologic findings in the lungs were significantly lower than in immunosuppressed animals. 4 A Korean study reported atypical presentations of MERS-CoV infection in three immunocompromised patients with delayed development of symptoms, a prolonged incubation period, and a persistent viral shedding without clinical deterioration. 5 All these peculiar presentations were probably influenced by the underlying immunological status of the patients, including the use of immunosuppressants. 5 More recently, a systematic review analyzed 110 immunosuppressed patients infected with SARS-CoV-2, mostly presenting cancer, along with transplantation and immunodeficiency. The results revealed a tendency towards a favorable disease course, as compared to the general population. The authors concluded that this phenomenon might be explained by a possible protective role of a weaker immune response, determining a milder disease presentation and, thus, underdiagnosis. 6 This article is protected by copyright. All rights reserved Understanding the potential harm or benefit of steroids in CoV-related disease is of immediate clinical importance. In theory, steroids may play a role in suppressing virus-driven lung inflammation, although increasing the time of viral clearance and viral shedding. In Table 1 , the effect of steroids on coronavirus clearance and patient survival is displayed. In a retrospective study, including 309 adults with MERS-CoV-caused ARDS, the administration of steroids did not lead to different 90-day mortality (odds ratio=0. 8 This article is protected by copyright. All rights reserved management of severe acute respiratory infection (released March 13, 2020) advises not to use steroids unless indicated for another reason. 16 In transplanted patients, steroids are used mainly as induction and anti-rejection agents and always less often as a "maintenance therapy". The recently published clinical recommendations from the American Association for the Study of Liver Diseases (AASLD) have reported that minimization of high-dose steroid dosage is recommended in immunosuppressed patients with COVID-19 but maintaining a sufficient dosage to avoid adrenal insufficiency. 17 Another statement recommended initiating therapy with steroids in patients with liver disease with or without COVID-19 who have strong indications for treatment like autoimmune hepatitis or graft rejection. 17 Various studies explored the impact of calcineurin inhibitors (CNI) cyclosporine (CyA) and tacrolimus (TAC) and their non-immunosuppressive derivatives on the in vitro and in vivo replication of coronaviruses. [18] [19] [20] [21] [22] CyA and TAC bind to different cellular cyclophilins in order to inhibit calcineurin, a calciumcalmodulin-activated serine/threonine-specific phosphatase. The calcineurin inhibition blocks the translocation of the nuclear factor of activated T cells from the cytosol into the nucleus, thereby preventing the transcription of several genes encoding for the key cytokines involved in the immunological mechanisms, like interleukin-2. Apart from this mechanism, cyclophilins are required by several viruses for their replication. 18 Interestingly, inhibition of cyclophilin by CyA can block the replication of CoV of all genera, including SARS-CoV, human CoV-229E, human CoV-NL-63, feline CoV, as well as avian infectious bronchitis virus. 19 Similarly, TAC strongly inhibits the growth of human coronaviruses SARS-CoV, human CoV-NL63, and human CoV-229E. 20 In-vitro and human ex-vivo explant cultures reported the synergic effect of two immunomodulatory agents, namely interferon-alpha and cyclosporine, as critical agents for the reduction of MERS-CoV replication. 21 Mycophenolic acid has also been shown to block the papain-like protease of MERS-CoV, therefore blocking the in vitro replication of the virus. 23 Due to the small number of reported transplant cases experiencing CoV infections, no clear clinical evidence exists on the real impact of the immunosuppressive drugs in the clinical practice yet. The AASLD interestingly stated that: "the immune response may be the main driver for pulmonary injury due to COVID-19 and that immunosuppression may be protective". 17 However, This article is protected by copyright. All rights reserved the recommendations for good clinical practice from most scientific societies are based on common sense rather than on evidence, as the latter is still lacking. 17 ,24 Only anecdotal experiences of solid organ transplant recipients experiencing CoV infections have been reported during SARS and MERS epidemics. 25, 26 Remarkably, among the 774 and 912 deaths reported in the two outbreaks of SARS in 2002 and MERS in 2012 respectively, only two transplanted cases were described in the literature. 25, 26 Likely, this number is an underestimation of reality, but it could reflect that transplant patients did not suffer from more severe forms of pulmonary disease compared to the general population during the previous CoV epidemics. Conversely, a more significant number of case reports and small series are consistently being published during the SARS-CoV-2 pandemics, many of which also reporting the details on the immunosuppressive regimen management ( Table 2) . 27 Table 3) . According to these data, the current COVID-19 pandemics has sadly affected the transplant population much more in-depth respect to the SARS and MERS outbreaks. Data reported by The Transplant Society (TTS) interestingly observed that high mortality rates (15-30%) were mainly reported in transplant recipients from countries with high COVID-19 incidence and high mortality rates in the general populations. On the opposite, low incidence and mortality rates were reported in transplant patients from low-incidence countries (https://tts.org/11-tts/news/692-tts-coronavirus). When data from large registries were reported, high fatality but low prevalence rates were observed. As an example, the European Renal Association Registry reported 231 (19.1%) deaths in 1,211 kidney transplant cases (https://era-edta-reg.org/index.jsp?p=covid19). This article is protected by copyright. All rights reserved The reported high fatality rate might be justified by several aspects, such as the higher median age and comorbidities of the transplanted population, besides the tendency to report the most severe cases respect to the uneventful ones. Data on COVID-19 in transplanted patients are still sparse, and the opportunity to obtain a global picture is still limited. A more reliable estimate of how lethal SARS-CoV-2 is to transplant recipients could be obtained after matching them by age and comorbidities with the general population. Up to now, only a large study focused on pediatric transplantation has been published exploring the potential prevalence of COVID-19 in transplanted cases. In detail, the preliminary experience of the pediatric Transplant Center of the Hospital Papa Giovanni XXIII in Bergamo, Italy, located in the "red zone" of the Italian outbreak, was reported. 56 Interestingly, this large series based on 700 children did not report any case of clinical pulmonary disease and only three positive cases. These data suggest that children, similarly to the general pediatric population, should develop a less aggressive course of COVID-19 also when immunosuppressed. 56 Data on the modification of immunosuppressive regimens in transplanted patients experiencing the SARS-CoV-2 infection are reported in Table 2 . Before infection, the most common baseline maintenance immunosuppression was CNI, MMF with or without steroids. In the 126 cases in which the post-COVID-19 immunosuppression therapy was detailed, the most common form of immunosuppression modification was the This article is protected by copyright. All rights reserved discontinuation of the antimetabolites MMF or azathioprine (n=41, 32.5%), followed by the discontinuation of the entire immunosuppression regimen (n=37, 29.4%), the discontinuation of the CNI (n=17, 13.5%), and the dose reduction of all the immunosuppressive drugs (n=10, 7.9%). Remarkably, 116/126 (92.1%) cases maintained or reintroduced steroids during the infection. In some cases, steroids were switched from oral to intravenous form following discontinuation or reduction of all the other drugs (n=26/126, 20.6%). From the data above, a divergence between clinical reality and societal recommendations emerges. As an example, the discontinuation of azathioprine, MMF, or CNI seems more common than just the dose reduction that was suggested by the AASLD in cases of lymphopenia, fever, or worsening pneumonia caused by Similarly, in consensus-based guidance derived from individual information of 19 transplant societies, only the reduction -rather than the discontinuation -of immunosuppression was This article is protected by copyright. All rights reserved scarce data on other viral diseases, in vitro data, case reports, small series, and international guidelines based on sound clinical practice and common sense. However, we attempted to summarize some considerations extrapolated from published data ( Table 4 ). The limitation of our work resides in the evolving body of literature on COVID-19 and transplantation, which is released daily and precludes a systematic approach in the review process. Besides, the heterogeneity of the reported cases and the limited information provided within the articles we analyzed, renders any conclusions speculative and should not be intended as guidance on patient management. Nevertheless, we intended to provide transplant physicians with a useful snapshot of the available reports on the topic and to frame this clinical data with the knowledge around previous coronavirus infections in immunocompromised and transplanted patients. The reported literature shows that CoV-positive transplanted patients treated with immunosuppressants such as steroids may present more intense and prolonged virus shedding, thereby increasing potentially the risk of transmission to contacts, including healthcare workers. 7, 8, 9, 11, 57 On the other side, the use of steroids in the treatment of ARDS showed controversial results, and moderate use is suggested. The cautious approach proposed by Shang et al. seems reasonable. Steroid use should be a) carefully weighed case by case in light of the potential benefits and harms; b) prudently administered in critically ill patients with COVID-19 pneumonia; c) as well as in patients regularly using steroids (such as transplanted patients), further use of steroids should be cautious; and, d) the dosage should be low-to-moderate (≤0.5-1 mg/kg/day methylprednisolone or equivalent), and the duration should be short (≤7 days). 15 As for the other immunosuppressive drugs, no clinical shreds of evidence exist concerning their impact in transplanted COVID-19 patients. Theoretically, in vitro studies showed that the use of CNI or mycophenolic acid might be a strategy to reduce viral replication. [17] [18] [19] [20] [21] [22] [23] Since no clinical studies exist on this aspect, caution is recommended when managing immunosuppressors in COVID-19 positive patients. In the presence of moderate illness, only a reduction of the immunosuppressive load should be considered. 17, 24 In severely ill patients with a high risk of ARDS and potential bacterial super-infections, several small clinical shreds of evidence reported the decision to discontinue the immunosuppression drugs. No studies exist on the potential interaction between immunosuppressants and the different antiviral drugs, including remdesivir, lopinavir/ritonavir, darunavir-cobicistat, interferon beta and (hydroxy)chloroquine used in the treatment of COVID-19. 58 However, increased trough levels of This article is protected by copyright. All rights reserved tacrolimus have been observed after patients received antiviral treatment, with subsequent nephrotoxicity. Consequently, it is essential to measure frequently the immunosuppressant plasma levels with the intent to prevent over-immunosuppression and to cautiously adopt or even avoid drugs such as interferon-beta and (hydroxy)chloroquine in transplanted patients which could lead to rejection or toxicity. 59, 60 In this context, it should be important to consult the University of Liverpool Drug Interactions Group document on the possible interactions using experimental COVID-19 Therapies (https://www.covid19-druginteractions.org), and to monitor the new studies of antiviral and immunomodulatory approaches for the treatment of COVID-19. 17 Tables Table 1. Effect of steroids administration in the presence of viral pneumonia caused by coronaviruses. The steroids adopted were: hydrocortisone, methylprednisolone, dexamethasone, and prednisolone. Impact on viral clearance Impact on survival Delayed clearance of viral RNA from respiratory tract (7) 90-day mortality OR=0.8 (95%CI=0.5-1.1; p=0.12) (7) Delayed clearance of viral RNA from the blood (8, 9) In case of severe pneumonia, protective effect (0/60 deaths vs. 11/130; p=0.018 (10) Delayed clearance of viral RNA from respiratory tract (11) HR=0 This article is protected by copyright. All rights reserved patients for the risk of rejection and toxicity. #13 Consult the drug interactions documents on the possible interactions using experimental COVID-19 therapies. #14 Monitor new studies of antiviral and immunomodulatory approaches for COVID-19 treatment. Molecular pathology of emerging coronavirus infections HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression Characteristics and Outcomes of Coronavirus Infection in Children: The Role of Viral Factors and an Immunocompromised State Pathogenicity and Viral Shedding of MERS-CoV in Immunocompromised Rhesus Macaques Atypical presentations of MERS-CoV infection in immunocompromised hosts How is immunosuppressive status affecting children and adults in SARS-CoV-2 infection? A systematic review Saudi Critical Care Trial Group. Corticosteroid therapy for critically ill patients with middle east respiratory syndrome SARS: systematic review of treatment effects Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease A retrospective cohort study of methylprednisolone therapy in severe patients with COVID-19 pneumonia Accepted Article This article is protected by copyright. All rights reserved Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury On the use of corticosteroids for 2019-nCoV pneumonia Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID-19 Pandemic: AASLD Expert Panel Consensus Statement. Hepatology Suppression of coronavirus replication by cyclophilin inhibitors The SARScoronavirus-host interactome: identification of cyclophilins as target for pan-coronavirus inhibitors Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506 Effect of interferon alpha and cyclosporine treatment separately and in combination on Middle East Respiratory Syndrome Coronavirus (MERS-CoV) replication in a human in-vitro and ex-vivo culture model Human coronavirus NL63 replication is cyclophilin A-dependent and inhibited by nonimmunosuppressive cyclosporine A-derivatives including Alisporivir Thiopurine analogs and mycophenolic acid synergistically inhibit the papain-like protease of Middle East respiratory syndrome coronavirus Solid Organ Transplantation Programs Facing Lack of Empiric Evidence in the COVID-19 Pandemic: A By-proxy Society Recommendation Consensus Approach MERS CoV infection in two renal transplant recipients: case report Severe Acute Respiratory Syndrome (SARS) in a liver transplant recipient and guidelines for donor SARS screening A single center observational study of the clinical characteristics and short-term outcome of 20 kidney transplant patients admitted for SARS-CoV2 pneumonia Covid-19 and Kidney Transplantation COVID-19 infection in kidney transplant recipients COVID-19 in long-term liver transplant patients: preliminary experience from an Italian transplant centre in Lombardy A Catabolic State in a Kidney Transplant Recipient with COVID-19 Early Impact of COVID-19 on Transplant Center Practices and Policies in the United States Immunosuppressive therapy maintenance in a kidney transplant recipient SARS-CoV-2 pneumonia: a case report A familial cluster, including a kidney transplant recipient Accepted Article This article is protected by copyright. All rights reserved 35. Columbia University Kidney Transplant Program. Early Description of Coronavirus Disease in Kidney Transplant Recipients in COVID-19 in solid organ transplant recipients: a single-center case series from Spain COVID-19 in kidney transplant recipients COVID-19 in a High-Risk Dual Heart and Kidney Transplant Recipient Case report of COVID-19 in a kidney transplant recipient: Does immunosuppression alter the clinical presentation? COVID-19 in posttransplant patients-report of 2 cases Fatal outcome in a liver transplant recipient with COVID-19 Managing COVID-19 in Renal Transplant Recipients: A Review of Recent Literature and Case Supporting Corticosteroidsparing Immunosuppression Earliest cases of coronavirus disease 2019 (COVID-19) identified in solid organ transplant recipients in the United States First cases of COVID-19 in heart transplantation from China Accepted Article This article is protected by copyright. All rights reserved Successful treatment of severe COVID-19 pneumonia in a liver transplant recipient The impact of the COVID-19 outbreak on Liver Transplantation programmes in Northern Italy First case of COVID-19 in a kidney transplant recipient treated with belatacept A Case of SARS-CoV-2-pneumonia with successful antiviral therapy in a 77-year-old male with heart transplant Severe COVID-19 in a renal transplant recipient: A focus on pharmacokinetics Novel Coronavirus (SARS-CoV-2) Infection in A Renal Transplant Recipient: Case Report Perioperative Presentation of COVID-19 Disease in a Liver Transplant Recipient SARS Cov2 infection in a renal transplanted patients. A case report Identification of Kidney Transplant Recipients with Clinical characteristics and immunosuppressants management of coronavirus disease 2019 in solid organ transplant recipients Successful recovery of COVID-19 pneumonia in a renal transplant recipient with long-term immunosuppression Coronaviruses and immunosuppressed patients. The facts during the third epidemic Coronavirus disease 2019: Implications of emerging infections for transplantation COVID-19: A Global Transplant Perspective on Successfully Navigating a Pandemic Interferon regulatory factors: Where to stand in transplantation Severe acute hepatitis related to hydroxychloroquine in a woman with mixed connective tissue disease Accepted Article This article is protected by copyright. All rights reserved Gandolfini